The FDA approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) of at least 1 as determined by an FDA-approved test.
The agency also granted regular approval to pembrolizumab as a single agent for patients who have recurrent or metastatic cervical cancer that progresses on or after